Recently, using AT2 receptor-deficient mice or a newly developed AT2 receptor agonist, compound 21 (C21), we and others have reported that direct AT2 receptor stimulation independent of AT1 receptor blockade ameliorated cognitive decline in cerebral ischemia model [31], AD, [32] or vascular dementia mouse model [33]. This evidence concerns the gene AGTR2 and vascular dementia.